Amgen Continues to Build Out Rare Disease Treatment Portfolio With $26B Horizon Acquisition

Powerhouse biotech drug developer Amgen is all set to fork over a hefty $26 billion to delve deeper into rare disease treatments with the buyout of drugmaker Horizon Therapeutics. The deal has been struck in the form of cash-for-share payments that shake out to $116.50 each for Horizon...